Nasus Pharma (NSRX) Common Equity (2024 - 2025)
Nasus Pharma's (NSRX) quarterly Common Equity came in at $2.8 million in Q4 2025, up 186.18% YoY from $967234.1 in Q4 2024, and up 164.16% on a QoQ basis from -$4.3 million in Q2 2025.
Nasus Pharma (NSRX) Common Equity (2024 - 2025) Analysis & Trends
Nasus Pharma (NSRX) has 2 years of Common Equity data on file, last reported at $2.8 million in Q4 2025.
- Quarterly Common Equity rose 186.18% year-over-year to $2.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.8 million (up 186.18% YoY) and the FY2025 annual result came in at $2.8 million, up 186.18% from the prior year.
- Common Equity grew to $2.8 million in Q4 2025, from -$4.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $2.8 million in Q4 2025 to a low of -$4.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.10 Bn | 631.35 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 469.76 Bn | 463.19 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 375.02 Bn | 367.88 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 303.10 Bn | 295.41 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.62 Bn | 252.72 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 236.38 Bn | 222.39 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 182.35 Bn | 179.17 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 159.63 Bn | 147.93 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Gsk | 106.06 Bn | 101.89 Bn | 8.24 Bn | 23.05 Bn |
| 10 | Nasus Pharma | 31.72 Mn | 31.72 Mn | - | 2.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.77 Mn |
| Jun 30, 2025 | -4.31 Mn |
| Dec 31, 2024 | -3.21 Mn |